| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 76 | 2024 | 155 | 23.290 |
Why?
|
| Angiogenesis Inhibitors | 99 | 2024 | 207 | 19.510 |
Why?
|
| Macular Edema | 55 | 2024 | 89 | 16.040 |
Why?
|
| Visual Acuity | 102 | 2025 | 808 | 12.660 |
Why?
|
| Ranibizumab | 59 | 2024 | 70 | 10.410 |
Why?
|
| Vascular Endothelial Growth Factor A | 86 | 2024 | 413 | 10.350 |
Why?
|
| Wet Macular Degeneration | 34 | 2024 | 41 | 10.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 51 | 2024 | 94 | 9.910 |
Why?
|
| Intravitreal Injections | 96 | 2024 | 144 | 9.400 |
Why?
|
| Macular Degeneration | 30 | 2024 | 113 | 8.920 |
Why?
|
| Tomography, Optical Coherence | 82 | 2025 | 517 | 8.830 |
Why?
|
| Recombinant Fusion Proteins | 51 | 2024 | 767 | 8.430 |
Why?
|
| Fluorescein Angiography | 61 | 2024 | 139 | 6.730 |
Why?
|
| Geographic Atrophy | 15 | 2024 | 22 | 6.510 |
Why?
|
| Macula Lutea | 17 | 2024 | 45 | 5.030 |
Why?
|
| Diabetes Mellitus | 19 | 2024 | 850 | 4.880 |
Why?
|
| Retinal Diseases | 17 | 2024 | 172 | 4.850 |
Why?
|
| Antibodies, Monoclonal, Humanized | 23 | 2024 | 489 | 4.720 |
Why?
|
| Retinal Detachment | 15 | 2023 | 83 | 4.660 |
Why?
|
| Vitrectomy | 25 | 2024 | 108 | 4.520 |
Why?
|
| Retinal Vein Occlusion | 17 | 2022 | 27 | 4.510 |
Why?
|
| Retinal Vessels | 24 | 2024 | 73 | 4.490 |
Why?
|
| Choroidal Neovascularization | 12 | 2023 | 29 | 4.400 |
Why?
|
| Retinal Perforations | 10 | 2024 | 27 | 3.780 |
Why?
|
| Laser Coagulation | 17 | 2023 | 129 | 3.650 |
Why?
|
| Bevacizumab | 20 | 2024 | 63 | 3.050 |
Why?
|
| Retina | 23 | 2024 | 456 | 2.710 |
Why?
|
| Scleral Buckling | 9 | 2022 | 13 | 2.190 |
Why?
|
| Humans | 239 | 2025 | 123254 | 2.180 |
Why?
|
| Choroid | 8 | 2024 | 39 | 2.150 |
Why?
|
| Glucocorticoids | 10 | 2024 | 378 | 2.120 |
Why?
|
| Endophthalmitis | 7 | 2016 | 76 | 2.060 |
Why?
|
| Aged | 89 | 2025 | 19173 | 2.030 |
Why?
|
| Middle Aged | 98 | 2025 | 26073 | 2.000 |
Why?
|
| Follow-Up Studies | 38 | 2025 | 5049 | 1.710 |
Why?
|
| Prospective Studies | 47 | 2024 | 6030 | 1.690 |
Why?
|
| Photography | 6 | 2022 | 92 | 1.670 |
Why?
|
| Aged, 80 and over | 45 | 2024 | 6385 | 1.640 |
Why?
|
| Peptides, Cyclic | 2 | 2023 | 52 | 1.590 |
Why?
|
| Male | 115 | 2025 | 60310 | 1.570 |
Why?
|
| Ischemia | 10 | 2021 | 344 | 1.560 |
Why?
|
| Female | 120 | 2025 | 65598 | 1.520 |
Why?
|
| Treatment Outcome | 53 | 2024 | 12165 | 1.480 |
Why?
|
| Fundus Oculi | 17 | 2024 | 62 | 1.400 |
Why?
|
| Vitreous Detachment | 3 | 2024 | 15 | 1.360 |
Why?
|
| Complement C3 | 4 | 2023 | 47 | 1.300 |
Why?
|
| Retrospective Studies | 54 | 2025 | 16056 | 1.280 |
Why?
|
| Endothelial Growth Factors | 12 | 2023 | 49 | 1.200 |
Why?
|
| Fovea Centralis | 4 | 2020 | 10 | 1.200 |
Why?
|
| Nerve Fibers | 3 | 2025 | 72 | 1.200 |
Why?
|
| Eye Infections, Bacterial | 3 | 2016 | 90 | 1.180 |
Why?
|
| Retinal Vasculitis | 4 | 2023 | 8 | 1.170 |
Why?
|
| Triamcinolone Acetonide | 4 | 2024 | 37 | 1.150 |
Why?
|
| Retinal Pigment Epithelium | 5 | 2024 | 35 | 1.140 |
Why?
|
| Complement Inactivating Agents | 3 | 2023 | 11 | 1.130 |
Why?
|
| Subretinal Fluid | 7 | 2024 | 12 | 1.090 |
Why?
|
| Disease Progression | 14 | 2025 | 2030 | 1.050 |
Why?
|
| Retinal Telangiectasis | 3 | 2025 | 5 | 1.020 |
Why?
|
| Epiretinal Membrane | 4 | 2024 | 15 | 0.990 |
Why?
|
| Adult | 48 | 2024 | 29079 | 0.920 |
Why?
|
| Double-Blind Method | 15 | 2024 | 1601 | 0.910 |
Why?
|
| Fluocinolone Acetonide | 4 | 2020 | 6 | 0.910 |
Why?
|
| Vitreous Body | 5 | 2024 | 105 | 0.870 |
Why?
|
| Cysts | 2 | 2024 | 100 | 0.870 |
Why?
|
| Retinal Vein | 3 | 2022 | 12 | 0.840 |
Why?
|
| Ophthalmology | 6 | 2024 | 197 | 0.840 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 1084 | 0.830 |
Why?
|
| Cataract | 3 | 2022 | 219 | 0.820 |
Why?
|
| Benchmarking | 1 | 2023 | 132 | 0.810 |
Why?
|
| Eye Infections, Fungal | 4 | 2014 | 77 | 0.790 |
Why?
|
| Edema | 2 | 2022 | 136 | 0.760 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 34 | 0.750 |
Why?
|
| Carbonic Anhydrases | 11 | 2003 | 25 | 0.740 |
Why?
|
| Neovascularization, Pathologic | 7 | 2018 | 240 | 0.740 |
Why?
|
| Ophthalmic Solutions | 2 | 2011 | 89 | 0.730 |
Why?
|
| Ophthalmoscopy | 3 | 2019 | 27 | 0.730 |
Why?
|
| Vision Disorders | 4 | 2023 | 210 | 0.710 |
Why?
|
| No-Show Patients | 1 | 2020 | 3 | 0.690 |
Why?
|
| Basement Membrane | 5 | 2024 | 46 | 0.690 |
Why?
|
| Vitreoretinal Surgery | 2 | 2021 | 8 | 0.690 |
Why?
|
| Lost to Follow-Up | 1 | 2020 | 32 | 0.680 |
Why?
|
| Retinal Hemorrhage | 2 | 2017 | 22 | 0.680 |
Why?
|
| Cataract Extraction | 3 | 2017 | 210 | 0.680 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 280 | 0.670 |
Why?
|
| Sensory Thresholds | 1 | 2019 | 33 | 0.660 |
Why?
|
| Postoperative Complications | 4 | 2017 | 3018 | 0.660 |
Why?
|
| Patient Dropouts | 1 | 2019 | 52 | 0.650 |
Why?
|
| Choroid Diseases | 1 | 2019 | 21 | 0.630 |
Why?
|
| Eye Diseases | 2 | 2011 | 113 | 0.620 |
Why?
|
| Drug Delivery Systems | 2 | 2022 | 182 | 0.620 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 363 | 0.590 |
Why?
|
| Microaneurysm | 3 | 2023 | 3 | 0.590 |
Why?
|
| Angiopoietin-2 | 3 | 2023 | 13 | 0.580 |
Why?
|
| Lasers | 2 | 2017 | 115 | 0.550 |
Why?
|
| Drug Administration Schedule | 6 | 2022 | 726 | 0.520 |
Why?
|
| Patient Compliance | 1 | 2019 | 470 | 0.520 |
Why?
|
| Lasers, Solid-State | 1 | 2016 | 16 | 0.520 |
Why?
|
| Retinitis | 1 | 2016 | 17 | 0.510 |
Why?
|
| Meningoencephalitis | 1 | 2016 | 19 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 1078 | 0.500 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 2397 | 0.490 |
Why?
|
| Time Factors | 10 | 2024 | 6222 | 0.490 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2018 | 119 | 0.490 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 116 | 0.490 |
Why?
|
| Vancomycin | 1 | 2017 | 218 | 0.480 |
Why?
|
| Clinical Protocols | 5 | 2022 | 234 | 0.470 |
Why?
|
| Cell Hypoxia | 12 | 2004 | 95 | 0.460 |
Why?
|
| Povidone-Iodine | 2 | 2011 | 9 | 0.460 |
Why?
|
| Injections, Intraocular | 3 | 2024 | 10 | 0.450 |
Why?
|
| West Nile Fever | 1 | 2016 | 139 | 0.440 |
Why?
|
| Precision Medicine | 2 | 2018 | 308 | 0.430 |
Why?
|
| Retinal Ganglion Cells | 2 | 2025 | 106 | 0.430 |
Why?
|
| Cryosurgery | 1 | 2013 | 46 | 0.430 |
Why?
|
| Fungi | 3 | 2014 | 69 | 0.430 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2004 | 236 | 0.430 |
Why?
|
| Atrophy | 6 | 2024 | 226 | 0.420 |
Why?
|
| Uveitis | 2 | 2024 | 35 | 0.410 |
Why?
|
| Biomarkers | 10 | 2024 | 2951 | 0.410 |
Why?
|
| Retinal Degeneration | 3 | 2025 | 91 | 0.410 |
Why?
|
| Choroid Neoplasms | 2 | 2013 | 25 | 0.400 |
Why?
|
| Transcription Factors | 10 | 2004 | 2586 | 0.400 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2022 | 6 | 0.400 |
Why?
|
| Nuclear Proteins | 9 | 2004 | 1268 | 0.400 |
Why?
|
| Antisepsis | 1 | 2011 | 9 | 0.390 |
Why?
|
| Mycoses | 2 | 2014 | 116 | 0.380 |
Why?
|
| Bacteria | 2 | 2016 | 483 | 0.380 |
Why?
|
| Ophthalmologists | 2 | 2024 | 17 | 0.380 |
Why?
|
| Eye | 2 | 2024 | 227 | 0.380 |
Why?
|
| Ciliary Body | 1 | 2011 | 31 | 0.370 |
Why?
|
| Retinal Neovascularization | 3 | 2020 | 14 | 0.370 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2004 | 352 | 0.370 |
Why?
|
| Kidney Neoplasms | 4 | 2004 | 429 | 0.370 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 264 | 0.370 |
Why?
|
| Algorithms | 6 | 2024 | 1597 | 0.360 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2004 | 467 | 0.360 |
Why?
|
| Aging | 1 | 2018 | 1185 | 0.360 |
Why?
|
| Uveal Neoplasms | 1 | 2011 | 54 | 0.360 |
Why?
|
| Retreatment | 4 | 2018 | 88 | 0.360 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 1009 | 0.350 |
Why?
|
| Retinal Drusen | 3 | 2024 | 7 | 0.350 |
Why?
|
| Regression Analysis | 3 | 2022 | 772 | 0.350 |
Why?
|
| Surgical Flaps | 2 | 2024 | 206 | 0.350 |
Why?
|
| Hospitals, University | 1 | 2010 | 96 | 0.350 |
Why?
|
| Neoplasm Proteins | 10 | 2004 | 668 | 0.340 |
Why?
|
| Cephalosporins | 1 | 2011 | 138 | 0.340 |
Why?
|
| Regional Blood Flow | 3 | 2019 | 213 | 0.330 |
Why?
|
| Drug Hypersensitivity | 1 | 2011 | 96 | 0.330 |
Why?
|
| Quality of Life | 4 | 2023 | 1932 | 0.330 |
Why?
|
| Pharmaceutical Preparations | 3 | 2023 | 79 | 0.330 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 128 | 0.320 |
Why?
|
| DNA-Binding Proteins | 8 | 2004 | 2054 | 0.320 |
Why?
|
| Cryptococcosis | 1 | 2009 | 42 | 0.320 |
Why?
|
| Oculomotor Nerve | 1 | 2008 | 5 | 0.310 |
Why?
|
| Risk Factors | 11 | 2024 | 10036 | 0.310 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2008 | 7 | 0.310 |
Why?
|
| Capillary Permeability | 2 | 2020 | 77 | 0.310 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2008 | 17 | 0.310 |
Why?
|
| Blindness | 2 | 2021 | 72 | 0.310 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2008 | 19 | 0.300 |
Why?
|
| Rhabdoid Tumor | 1 | 2008 | 49 | 0.300 |
Why?
|
| Exudates and Transudates | 2 | 2021 | 22 | 0.300 |
Why?
|
| Antigens, Neoplasm | 8 | 2003 | 381 | 0.300 |
Why?
|
| Combined Modality Therapy | 8 | 2020 | 1239 | 0.290 |
Why?
|
| Corneal Ulcer | 1 | 2008 | 56 | 0.290 |
Why?
|
| Vitelliform Macular Dystrophy | 2 | 2024 | 2 | 0.290 |
Why?
|
| Single-Blind Method | 2 | 2021 | 235 | 0.280 |
Why?
|
| Teratoma | 1 | 2008 | 123 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1253 | 0.280 |
Why?
|
| Cross Infection | 1 | 2010 | 330 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2002 | 1873 | 0.270 |
Why?
|
| Young Adult | 7 | 2024 | 8867 | 0.270 |
Why?
|
| Biomarkers, Tumor | 7 | 2008 | 1437 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2004 | 1680 | 0.250 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 2852 | 0.250 |
Why?
|
| United States | 9 | 2024 | 10663 | 0.250 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 3382 | 0.250 |
Why?
|
| Melanoma | 2 | 2013 | 824 | 0.240 |
Why?
|
| Adolescent | 6 | 2024 | 19131 | 0.240 |
Why?
|
| Silicone Oils | 1 | 2024 | 11 | 0.240 |
Why?
|
| Intraocular Pressure | 2 | 2024 | 144 | 0.230 |
Why?
|
| Oxygen | 6 | 2018 | 550 | 0.230 |
Why?
|
| Aqueous Humor | 2 | 2022 | 27 | 0.230 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2006 | 148 | 0.230 |
Why?
|
| Angiopoietins | 2 | 2021 | 20 | 0.230 |
Why?
|
| Drug Approval | 1 | 2024 | 40 | 0.230 |
Why?
|
| Myopia | 1 | 2006 | 193 | 0.230 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2002 | 63 | 0.230 |
Why?
|
| Complement C5 | 1 | 2023 | 7 | 0.230 |
Why?
|
| Hypoxia | 4 | 2004 | 248 | 0.220 |
Why?
|
| Cyclin D1 | 1 | 2004 | 112 | 0.220 |
Why?
|
| Ligases | 2 | 2000 | 46 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 9 | 2004 | 1063 | 0.220 |
Why?
|
| Photochemotherapy | 2 | 2022 | 34 | 0.220 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 153 | 0.220 |
Why?
|
| Entropy | 1 | 2023 | 26 | 0.220 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 149 | 0.220 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2023 | 6 | 0.220 |
Why?
|
| Evidence-Based Medicine | 2 | 2024 | 623 | 0.210 |
Why?
|
| Traction | 1 | 2022 | 9 | 0.210 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 9 | 2004 | 98 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2013 | 255 | 0.200 |
Why?
|
| Eye Neoplasms | 2 | 2013 | 50 | 0.200 |
Why?
|
| Prone Position | 1 | 2022 | 31 | 0.200 |
Why?
|
| Porphyrins | 1 | 2022 | 15 | 0.200 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2022 | 6 | 0.200 |
Why?
|
| Hypoxia-Inducible Factor 1 | 8 | 2004 | 19 | 0.200 |
Why?
|
| Delphi Technique | 1 | 2023 | 203 | 0.200 |
Why?
|
| Biomedical Research | 2 | 2019 | 518 | 0.200 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 29 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2012 | 334 | 0.190 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 361 | 0.190 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1876 | 0.190 |
Why?
|
| Equipment Design | 2 | 2020 | 604 | 0.190 |
Why?
|
| Registries | 3 | 2023 | 1397 | 0.190 |
Why?
|
| Postoperative Period | 2 | 2020 | 332 | 0.190 |
Why?
|
| Confidence Intervals | 1 | 2021 | 279 | 0.190 |
Why?
|
| Blood-Retinal Barrier | 2 | 2020 | 3 | 0.180 |
Why?
|
| Drug Implants | 2 | 2020 | 42 | 0.180 |
Why?
|
| Cytokines | 3 | 2022 | 1283 | 0.180 |
Why?
|
| Cornea | 1 | 2006 | 645 | 0.180 |
Why?
|
| Computer Systems | 1 | 2021 | 38 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 1688 | 0.180 |
Why?
|
| Videoconferencing | 1 | 2020 | 21 | 0.180 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2020 | 61 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 163 | 0.170 |
Why?
|
| Consensus | 1 | 2023 | 610 | 0.170 |
Why?
|
| Fractals | 1 | 2019 | 2 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 19 | 0.170 |
Why?
|
| Microcirculation | 2 | 2019 | 93 | 0.170 |
Why?
|
| Biological Products | 1 | 2021 | 113 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2020 | 169 | 0.160 |
Why?
|
| Income | 1 | 2020 | 133 | 0.160 |
Why?
|
| Recurrence | 3 | 2019 | 1418 | 0.160 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1314 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2019 | 179 | 0.160 |
Why?
|
| Insurance Coverage | 1 | 2020 | 121 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 501 | 0.160 |
Why?
|
| Antifungal Agents | 3 | 2014 | 286 | 0.150 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 110 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 154 | 0.150 |
Why?
|
| Proteins | 2 | 2000 | 1040 | 0.150 |
Why?
|
| Breast Neoplasms | 5 | 2004 | 2478 | 0.150 |
Why?
|
| Necrosis | 7 | 2004 | 205 | 0.150 |
Why?
|
| Visual Prosthesis | 1 | 2017 | 4 | 0.150 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 97 | 0.150 |
Why?
|
| Vision, Low | 1 | 2017 | 14 | 0.150 |
Why?
|
| Ultrasonography | 3 | 2024 | 942 | 0.140 |
Why?
|
| Retinitis Pigmentosa | 1 | 2017 | 84 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.140 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 18 | 0.130 |
Why?
|
| Legislation, Drug | 1 | 2016 | 9 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 143 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2022 | 4705 | 0.130 |
Why?
|
| Beryllium | 1 | 2016 | 3 | 0.130 |
Why?
|
| Administration, Topical | 1 | 2016 | 141 | 0.130 |
Why?
|
| Lung Neoplasms | 4 | 2012 | 1591 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 420 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2002 | 202 | 0.130 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 1142 | 0.120 |
Why?
|
| Therapeutic Equivalency | 1 | 2015 | 13 | 0.120 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2015 | 35 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 357 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
|
| Endotamponade | 2 | 2024 | 9 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2023 | 49 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2004 | 35 | 0.110 |
Why?
|
| Fluconazole | 2 | 2014 | 47 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2018 | 387 | 0.110 |
Why?
|
| Amphotericin B | 2 | 2014 | 90 | 0.110 |
Why?
|
| von Hippel-Lindau Disease | 3 | 2002 | 18 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 714 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 711 | 0.110 |
Why?
|
| History, 18th Century | 1 | 2013 | 69 | 0.100 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 84 | 0.100 |
Why?
|
| Carbonic Anhydrase IX | 8 | 2003 | 12 | 0.100 |
Why?
|
| Telemedicine | 1 | 2018 | 426 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2016 | 1122 | 0.100 |
Why?
|
| Anterior Chamber | 1 | 2012 | 57 | 0.100 |
Why?
|
| Chlorhexidine | 1 | 2011 | 45 | 0.090 |
Why?
|
| Lymphokines | 2 | 2002 | 66 | 0.090 |
Why?
|
| Drug Costs | 1 | 2011 | 60 | 0.090 |
Why?
|
| Retinopathy of Prematurity | 1 | 2011 | 56 | 0.090 |
Why?
|
| Liver Function Tests | 1 | 2011 | 101 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2806 | 0.090 |
Why?
|
| Pandemics | 3 | 2024 | 1100 | 0.090 |
Why?
|
| Refraction, Ocular | 1 | 2013 | 298 | 0.090 |
Why?
|
| Glucose | 1 | 2015 | 880 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2013 | 246 | 0.090 |
Why?
|
| Florida | 1 | 2010 | 73 | 0.090 |
Why?
|
| Prognosis | 7 | 2024 | 4515 | 0.090 |
Why?
|
| Decision Making | 1 | 2015 | 652 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2021 | 4499 | 0.090 |
Why?
|
| Acute Disease | 2 | 2010 | 1093 | 0.090 |
Why?
|
| Neoplasms | 2 | 2004 | 2757 | 0.090 |
Why?
|
| Penicillins | 1 | 2011 | 154 | 0.090 |
Why?
|
| Child | 3 | 2024 | 24263 | 0.080 |
Why?
|
| Immunohistochemistry | 6 | 2003 | 1687 | 0.080 |
Why?
|
| Flucytosine | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cryptococcus neoformans | 1 | 2009 | 20 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 67 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 268 | 0.080 |
Why?
|
| In Situ Hybridization | 4 | 2004 | 472 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 174 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2011 | 348 | 0.080 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2008 | 2 | 0.080 |
Why?
|
| Incidence | 1 | 2016 | 3052 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2008 | 604 | 0.080 |
Why?
|
| Subarachnoid Space | 1 | 2008 | 24 | 0.080 |
Why?
|
| Mesencephalon | 1 | 2008 | 42 | 0.080 |
Why?
|
| Eye Enucleation | 1 | 2008 | 54 | 0.080 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2008 | 53 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2001 | 651 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2844 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2008 | 355 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2008 | 335 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3239 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2003 | 1102 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 2001 | 481 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2002 | 545 | 0.070 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 41 | 0.070 |
Why?
|
| Capillaries | 2 | 2017 | 66 | 0.070 |
Why?
|
| Hydrocephalus | 1 | 2008 | 242 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 299 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 1390 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2024 | 3549 | 0.060 |
Why?
|
| Transfection | 3 | 2004 | 1068 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2003 | 381 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2004 | 313 | 0.060 |
Why?
|
| Suspensions | 1 | 2024 | 9 | 0.060 |
Why?
|
| Search Engine | 1 | 2023 | 6 | 0.060 |
Why?
|
| Inflammation | 2 | 2022 | 1405 | 0.060 |
Why?
|
| RNA, Messenger | 4 | 2004 | 2815 | 0.050 |
Why?
|
| Plasmids | 2 | 2004 | 512 | 0.050 |
Why?
|
| Vitreous Hemorrhage | 1 | 2023 | 9 | 0.050 |
Why?
|
| Equivalence Trials as Topic | 1 | 2023 | 12 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2023 | 9 | 0.050 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Nephrons | 1 | 2002 | 20 | 0.050 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 24 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1117 | 0.050 |
Why?
|
| Indocyanine Green | 2 | 2015 | 58 | 0.050 |
Why?
|
| Syringes | 1 | 2022 | 24 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2022 | 33 | 0.050 |
Why?
|
| Machine Learning | 1 | 2024 | 222 | 0.050 |
Why?
|
| Cell Division | 2 | 2001 | 781 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2004 | 862 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2023 | 228 | 0.050 |
Why?
|
| Pentosan Sulfuric Polyester | 1 | 2021 | 1 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 293 | 0.050 |
Why?
|
| Cell Adhesion Molecule-1 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1232 | 0.050 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2021 | 8 | 0.050 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2021 | 26 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 2015 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 37 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2021 | 41 | 0.050 |
Why?
|
| RNA | 2 | 2004 | 570 | 0.050 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2001 | 41 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2002 | 1013 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2000 | 54 | 0.050 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2001 | 83 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 132 | 0.050 |
Why?
|
| Organ Size | 1 | 2022 | 419 | 0.050 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2000 | 25 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2001 | 89 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 262 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 1311 | 0.050 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 61 | 0.040 |
Why?
|
| Slit Lamp Microscopy | 1 | 2020 | 5 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2001 | 202 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2000 | 45 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 274 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 156 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2001 | 104 | 0.040 |
Why?
|
| Observation | 1 | 2020 | 42 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2001 | 809 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 543 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 408 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2019 | 62 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2000 | 383 | 0.040 |
Why?
|
| Calcinosis | 1 | 2001 | 170 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2000 | 1340 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 679 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 424 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2004 | 816 | 0.040 |
Why?
|
| Breast | 1 | 2001 | 214 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 395 | 0.040 |
Why?
|
| Protein Binding | 2 | 2020 | 1741 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 220 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 679 | 0.040 |
Why?
|
| Cells | 1 | 1999 | 27 | 0.040 |
Why?
|
| Gene Expression Regulation | 4 | 2004 | 2525 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 625 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 645 | 0.040 |
Why?
|
| Specialization | 1 | 2019 | 76 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 36 | 0.040 |
Why?
|
| Carcinoma | 1 | 2000 | 278 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 80 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 458 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 284 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2000 | 760 | 0.040 |
Why?
|
| Caveolins | 1 | 1997 | 15 | 0.040 |
Why?
|
| Electroretinography | 1 | 2017 | 114 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 111 | 0.030 |
Why?
|
| Infant | 2 | 2011 | 12377 | 0.030 |
Why?
|
| European Union | 1 | 2016 | 13 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 580 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2058 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 434 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 378 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 606 | 0.030 |
Why?
|
| Gene Expression | 1 | 2001 | 1565 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 810 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2015 | 19 | 0.030 |
Why?
|
| Phenotype | 2 | 2021 | 4227 | 0.030 |
Why?
|
| Voriconazole | 1 | 2014 | 35 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 673 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2003 | 1473 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1801 | 0.030 |
Why?
|
| COS Cells | 2 | 2004 | 273 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1997 | 617 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 254 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1385 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 798 | 0.030 |
Why?
|
| Visual Fields | 1 | 2014 | 133 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 301 | 0.030 |
Why?
|
| Light Coagulation | 1 | 2013 | 24 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2004 | 138 | 0.030 |
Why?
|
| Nevus | 1 | 2013 | 35 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 45 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2022 | 13918 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2002 | 261 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 788 | 0.020 |
Why?
|
| Retinoblastoma | 1 | 2013 | 108 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 356 | 0.020 |
Why?
|
| Hemangioma | 1 | 2013 | 95 | 0.020 |
Why?
|
| Retinal Neoplasms | 1 | 2013 | 98 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2013 | 141 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 782 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 2001 | 103 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 73 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 796 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2407 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1997 | 1523 | 0.020 |
Why?
|
| Fluorescence | 1 | 2009 | 93 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2009 | 74 | 0.020 |
Why?
|
| Response Elements | 2 | 1999 | 97 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1237 | 0.020 |
Why?
|
| Mutation | 1 | 2000 | 5765 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 1116 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2004 | 23 | 0.010 |
Why?
|
| Mixed Function Oxygenases | 1 | 2004 | 32 | 0.010 |
Why?
|
| Immune Sera | 1 | 2004 | 95 | 0.010 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2004 | 35 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 58 | 0.010 |
Why?
|
| Doxycycline | 1 | 2004 | 115 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 383 | 0.010 |
Why?
|
| Animals | 5 | 2004 | 33837 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 19 | 0.010 |
Why?
|
| Apoptosis | 2 | 2002 | 1787 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 330 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2002 | 29 | 0.010 |
Why?
|
| RNA Interference | 1 | 2004 | 496 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2002 | 24 | 0.010 |
Why?
|
| RNA Probes | 1 | 2002 | 30 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2002 | 39 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 665 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 225 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 124 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 999 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 697 | 0.010 |
Why?
|
| Thymidine Phosphorylase | 1 | 2001 | 12 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2001 | 34 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2001 | 54 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 660 | 0.010 |
Why?
|
| England | 1 | 2001 | 57 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2001 | 85 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2002 | 173 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2002 | 330 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2001 | 135 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 516 | 0.010 |
Why?
|
| Mice | 3 | 2004 | 17546 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 419 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2001 | 283 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1289 | 0.010 |
Why?
|
| Cobalt | 1 | 1999 | 17 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 529 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1413 | 0.010 |
Why?
|
| Iron Chelating Agents | 1 | 1999 | 14 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 858 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2772 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1703 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1999 | 90 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 1999 | 114 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8112 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2001 | 501 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 2001 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 1999 | 261 | 0.010 |
Why?
|
| Genes, fos | 1 | 1997 | 16 | 0.010 |
Why?
|
| Mammals | 1 | 1999 | 261 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 1997 | 46 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2001 | 1211 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1997 | 129 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 1022 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1999 | 807 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2001 | 713 | 0.010 |
Why?
|
| Genes, ras | 1 | 1997 | 96 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 2115 | 0.010 |
Why?
|
| Lung | 1 | 2003 | 1465 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 1997 | 482 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 994 | 0.010 |
Why?
|